

Comparison of Fully-Covered vs Partially Covered Self-Expanding Metallic Stents for Palliative Treatment of Inoperable Esophageal Malignancy: A Systematic Review and Meta-Analysis

Chunmei Wang

Huaihe Hospital of Henan University

Hua Wei

Huaihe Hospital of Henan University

Yuxia Li (✉ ley697@163.com)

Huaihe Hospital of Henan University <https://orcid.org/0000-0001-9381-0851>

Research article

Keywords: Esophageal cancer, Meta-analysis, Palliative treatment, Dysphagia

Posted Date: November 5th, 2019

DOI: <https://doi.org/10.21203/rs.2.16864/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on January 30th, 2020. See the published version at <https://doi.org/10.1186/s12885-020-6564-6>.

Abstract

Purpose: This study aimed to compare clinical outcomes following placement of fully covered self-expanding metallic stents (FCSEMS) vs partially covered self-expanding metallic stents (PCSEMS) for palliative treatment of inoperable esophageal cancer.

Materials and Methods: We searched PubMed, ScienceDirect, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) databases from inception up to 10 th July 2019. Studies comparing clinical outcomes with FCSEMS vs PCSEMS in patients with inoperable esophageal cancer requiring palliative treatment for dysphagia were included.

Results: Five studies were included in the review. 299 patients received FCSEMS while 313 patients received PCSEMS in the five studies. Improvement in dysphagia was reported with both FCSEMS and PCSEMS in the included studies. Meta-analysis indicated no significant difference in technical success between the two groups (Odds ratio [OR] 1.32, 95%CI 0.30-5.03, P= 0.78; I² =12%). There was no difference in the rates of stent migration between FCSEMS and PCSEMS (OR 1.32, 95%CI 0.30-5.03, P= 0.78; I² =12%). Similarly, there was no difference between the two stents for obstruction due to tissue growth (OR 0.86, 95%CI 0.51-1.44, P= 0.56; I² =7%) or by food (OR 0.33, 95%CI 0.10-1.06, P= 0.06; I² =23%). Incidence of bleeding (OR 0.57, 95%CI 0.21-1.58, P= 0.28; I² =0%) and chest pain (OR 1.06, 95%CI 0.44-2.57, P= 0.89; I² =0%) was similar in the two groups. Sub-group analysis of RCTs and non-RCTs produced similar results. The overall quality of studies was not high.

Conclusion: Our results indicate that there is no difference in technical success, stent migration, and stent obstruction, with FCSEMS or PCSEMS when used for palliative treatment of esophageal malignancy. Further RCTs are required to provide stronger evidence on this topic.

Background

With a 5-year survival rate of less than 20%, esophageal cancers are among the leading causes of cancer-related death worldwide[1]. At least 50% of all esophageal malignancies have an incurable disease at presentation[2]. Palliative treatment aimed at reduction of dysphagia and improving oral intake; is the primary goal for such patients. Over the past few decades, endoscopically placed self-expandable metallic stents (SEMS) have become a treatment of choice for palliative management[3]. SEMS consist of a cylindrical metallic frame that exerts a self-expansive force until it reaches its maximum fixed diameter[4]. It thereby expands the narrowed esophageal passage, rapidly restoring luminal patency, maintaining nutritional intake and improving quality of life[5].

Although rarely used now, the uncovered SEMS introduced in the 1990s were associated with a high reintervention rate due to stent obstruction secondary to a tumor or inflammatory tissue in-growth[6]. To overcome this complication, fully-covered SEMS (FCSEMS) were introduced with an outer synthetic coating of silicone or polyurethane derivatives. The covering prevents embedding of the stent in the esophageal wall and tissue in-growth in the lumen[7]. The covering also stops the extravasation of ingested oral contents in cases of esophageal fistula. Another advantage is that FCSEMS can be easily removed under endoscopic and/or fluoroscopic guidance. However, the lack of embedding in the esophageal wall makes them prone to migration as compared to uncovered stents[4]. To derive benefits of both uncovered SEMS and FCSEMS, partially covered SEMS (PCSEMS) were designed[8]. The covering in the case of PCSEMS is limited only to the stent body while the proximal and distal flanges remain uncovered thereby promoting embedding in the esophageal wall. This feature is believed to reduce the incidence of stent migration[3].

To date, a number of clinical reports have been published demonstrating good clinical results with both FCSEMS[9,10] and PCSEMS[8,11]. However, literature comparing the clinical outcomes of the two stents is limited. Therefore, the present study was designed to systematically search the literature and analyze evidence comparing the clinical outcomes following placement of FCSEMS and PCSEMS for palliative treatment of inoperable esophageal cancer.

Methods

Search strategy

This systematic review and meta-analysis was conducted following the guidelines of the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses)[12] and Cochrane Handbook for Systematic Reviews of Intervention[13]. We searched PubMed, ScienceDirect, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) databases from inception up to 10th July 2019. Search items used were: "esophageal cancer"; "esophageal dysphagia"; "esophagus"; "malignancy"; "stent"; "metallic stent" and "palliative treatment". The search strategy for PubMed database is presented in Table 1. Additionally, references of included studies and review articles on the subject were analyzed for identification of any additional studies. Two reviewers independently performed the literature search. Citations were initially screened at the title and abstract level. Full texts of selected articles were then analysed for inclusion in the review. Disagreements were resolved by discussion.

Inclusion criteria

We used the PICOS (Population, Intervention, Comparison, Outcome, and Study design) outline for including studies. We included randomised controlled trials (RCTs), quasi-RCTs, prospective/retrospective cohort studies conducted on adult patients with inoperable esophageal cancer requiring palliative treatment for dysphagia (*Population*); evaluating any kind of FCSEMS (*Intervention*); comparing it with any kind of PCSEMS (*Comparison*) and assessing technical and/or clinical success, stent migration and complications (*Outcomes*). We excluded studies conducted on benign esophageal lesions, studies utilizing irradiated stents and those with anti-reflux mechanisms, studies comparing uncovered stents with FCSEMS or PCSEMS. Additionally, we excluded non-English language studies, studies comparing less than 5 patients, duplicate reports, case-series and case reports.

Data Extraction and Outcomes

Data was extracted from the included trials by two independent reviewers using an abstraction form. The following details were sourced: Authors, publication year, sample size, baseline and demographic details, type of SEMs used, technical and clinical success rates, stent migration, stent obstruction and other complications. Authors were contacted via email for missing data.

Primary outcomes were the incidence of success (technical and/or clinical) and stent migration.

Secondary outcomes were the incidence of stent obstruction by tissue growth or food and other complications. Technical success was defined as endoscopic placement of SEMs in the intended position. The definition of clinical success was as per the included study. When multiple stents were compared in a study, data for all types of FCSEMs and PCSEMs were extracted.

Risk of bias

For quality assessment of randomised controlled studies (RCTs), the Cochrane Collaboration risk assessment tool for RCTs was used[14]. Studies were rated as low risk, high risk, or unclear risk of bias for: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Remaining studies were analyzed by the risk of bias assessment tool for non-randomized studies (RoBANS)[15]. Studies were rated as low risk, high risk, or unclear risk of bias for: Selection of participants, confounding variables, intervention measurements, blinding of outcome assessment, incomplete outcome data, selective outcome reporting.

Statistical analysis

Review Manager (RevMan, version 5.3; Nordic Cochrane Centre [Cochrane Collaboration], Copenhagen, Denmark; 2014) was used for the meta-analysis. Outcomes was summarized using the Mantel-Haenszel Odds Ratios (OR) with 95% confidence interval (CI). A random-effects model was used to calculate the pooled effect size. Heterogeneity was calculated using I^2 statistic. I^2 values of 25-50% represented low, values of 50-75% medium and >75% represented substantial heterogeneity. Sub-group analysis was conducted for RCTs and non-RCTs. Publication bias was not assessed due to limited studies included in the review.

Results

A total of 565 records were identified by database searching (Figure 1). Fifteen articles were analyzed by their full-texts. Ten studies were excluded[16–25]. Detailed reasons for exclusion are presented in Table 2. Five articles[26–30] met the inclusion criteria and were analyzed in this systematic review and meta-analysis.

The characteristics of included studies are presented in Table 3. The mean age of patients in the included studies varied from 63.6 to 72.2 years. Three studies were RCTs[27–29], one was a retrospective review[30] while one was a prospective study[26]. A total of 299 patients received FCSEMs while 313 patients received PCSEMs across the five studies. The types of FCSEMs varied across trials. Two studies[28,29] used the WallFlex fully-covered stent (Boston Scientific, Natick, Massachusetts, USA), while SX- ELLA® (ELLA-CS, Hradec Králové, Czech Republic), Niti-S stent (Taewoong Medical, Seoul, Korea) and Z-stent (Wilson-Cook Europe, Bjaeverskov, Denmark) were used in one study each. The use of Ultraflex® NG, (Boston Scientific, Natick, Massachusetts, USA) as PCSEMs was common with four studies[26–28,30] reporting its use. In one study[26], two types of PCSEMs [Ultraflex® NG and Flamingo Wallstent (Microvasive/Boston Scientific)] were compared with the fully-covered Z-stent. We included data for both these PCSEMs for the meta-analysis. Dysphagia was scored in all studies according to the internationally used scoring system: score 0, able to consume a normal diet; score 1, dysphagia with certain solid foods; score 2, able to swallow semisolid soft foods; score 3, able to swallow liquids only; score 4, complete dysphagia. The malignancy was frequently located in the distal esophagus and cardia across all five studies.

Outcomes

Outcomes of included studies are presented in Table 4. Definitions of clinical success, i.e. improvement in dysphagia scores varied across studies. Hence, data was not pooled for a meta-analysis and is presented in a descriptive form.

Lárraga et al[30] defined clinical success as dysphagia reduction of equal to or greater than 2 grades. Clinical success was reported in 90.2% patients with FCSEMs and 89.6% patients with PCSEMs with no statistical significant difference between the two groups. Didden et al[29] reported clinical success as at least 1 point reduction in dysphagia score. With 83% success with FCSEMs and 88% success with PCSEMs, there was no difference between the two stents. Persson et al[28] compared pre and post dysphagia scores using three instruments; the Watson dysphagia score[31], the Ogilvie score[32] and a symptom-oriented quality of life instrument that has a module that captures information regarding swallowing difficulties (QLQ-OG25)[33]. No statistical significant difference was seen between the two groups with any scoring instrument. Verschuur et al[27] reported an improvement of dysphagia scores from a median of 3 (liquids only) to 1 (ability to eat some solid food) with both FCSEMs and PCSEMs.

Four studies[27–30] reported data on technical success. Pooled data of 159 patients in the FCSEMs group and 167 patients in the PCSEMs group indicated no significant difference between the two groups (OR 1.22, 95%CI 0.30–5.03, $P = 0.78$; $I^2 = 12\%$)(Figure 2). Since the only non-RCT[30] included in this analysis reported 100% success with both FCSEMs and PCSEMs, the pooled estimate is effectively an analysis of RCTs only.

Data on stent migration was reported by all five studies[26–30]. Meta-analysis indicated no statistical significant difference in the rates of stent migration between FCSEMs and PCSEMs (OR 0.60, 95%CI 0.35–1.02, $P = 0.06$; $I^2 = 8\%$) (Figure 3). Results were similar for sub-group analysis of RCTs (OR 0.70, 95%CI 0.35–1.37, $P = 0.30$; $I^2 = 0\%$) and non-RCTs (OR 0.53, 95%CI 0.18–1.55, $P = 0.25$; $I^2 = 50\%$) (Figure 3).

Incidence of stent obstruction by tissue growth or food impaction was also reported by all five included studies[26–30]. Incidence of stent obstruction due to tissue growth was 12.37% (37/299) in the FCSEMS group and 14.69% (46/313) in the PCSEMS group. Pooled analysis demonstrated no statistical significant difference between the two groups (OR 0.86, 95%CI 0.51–1.44, $P = 0.56$; $I^2 = 7\%$) (Figure 4). Subgroup analysis for RCTs (OR 0.65, 95%CI 0.31–1.35, $P = 0.25$; $I^2 = 0\%$) and non-RCTs (OR 0.99, 95%CI 0.36–2.68, $P = 0.98$; $I^2 = 45\%$) also produced a similar result (Figure 4). The incidence of stent obstruction by food was higher in PCSEMS (7.3%) as compared to FCSEMS (1.6%). However, the pooled effect remained statistically non-significant (OR 0.33, 95%CI 0.10–1.06, $P = 0.06$; $I^2 = 23\%$) (Figure 5). Results for sub-group analysis of RCTs (OR 0.40, 95%CI 0.05–3.30, $P = 0.39$; $I^2 = 27\%$) and non-RCTs (OR 0.30, 95%CI 0.06–1.55, $P = 0.15$; $I^2 = 46\%$) were also non-significant (Figure 5).

Since the definition of remaining complications varied across studies, only specific complications with sufficient available data were pooled for a meta-analysis. Data on post-operative bleeding and chest pain was available from three studies[27,29,30]. Our results demonstrate no statistical significant difference in the incidence of bleeding between the two groups (OR 0.57, 95%CI 0.21–1.58, $P = 0.28$; $I^2 = 0\%$) (Figure 6). Similarly, there was no difference in the incidence of chest pain between FCSEMS and PCSEMS (OR 1.06, 95%CI 0.44–2.57, $P = 0.89$; $I^2 = 0\%$) (Figure 7). No difference in results were noted in sub-group analysis of RCTs and non-RCTs for both these complications (Figure 6 & 7).

Risk of bias assessment

The authors judgement of risk of bias assessment of RCTs is presented in Table 5. Adequate method of random sequence generation was followed by all three RCTs[27–29]. Allocation concealment[29] and blinding of participants[28] was reported by one trial each. Blinding of outcome assessment was not reported in any trial. Only one RCT was preregistered[29]. Risk of bias assessment according to RoBANS tool for non-RCTs is presented in Table 6.

Discussion

Palliative treatment for inoperable esophageal cancer has evolved considerably over the last few decades. SEMs have completely replaced the earlier generation plastic prosthesis due to a number of advantages[34]. SEMs are technically easy to place as they require minimum dilation before placement and have small delivery catheters. Due to the greater lumen diameter and inherent flexibility of the stent, swallowing is better as compared to plastic prosthetic devices[34,35]. Since its introduction, SEMs have also undergone multiple design changes to improve outcomes and reduce complications[3]. The uncovered SEMs had a problem of tumour ingrowth and difficulty of removal or repositioning after placement[35]. With the introduction of FCSEMS and PCSEMS, the uncovered SEMs have become more or less obsolete[4].

Owing to the limited comparative evidence between FCSEMS and PCSEMS, one of the primary objectives of this study was to compare clinical and technical success rates between the two devices. Our results suggests that; technical success, indicating successful placement of stent on the day the of planned procedure is not significantly different between the two SEMs. A very high technical success rate of 96.8% with FCSEMS and 96.4% with PCSEMS was pooled in our analysis. However, difference in definitions of clinical success and presentation of data, precluded a pooled analysis for reduction of dysphagia scores. A number of single-arm longitudinal studies have reported improvement in dysphagia scores with both FCSEMS and PCSEMS[7–9,36]. Repici et al[36] in prospective multi-centre non-randomised study of 82 patients reported an improvement of dysphagia scores from a mean of 3 to a mean of 1 ($p < 0.001$) at 4 weeks following placement of Wallflex FCSEMS. Likewise, Saranovic et al[37] have reported an improvement of dysphagia scores from 2.67 to 0.05 (on 0–4 scale) after 4 weeks, using the Ultraflex PCSEMS in 98 patients. Similar results were reported by all the four studies[27–30] reporting dysphagia outcomes in our review. Descriptive analysis of the four studies[27–30] suggests the difference the in basic design of FCSEMS and PCSEMS does not seem to have an impact on clinical success.

An important rationale of different design pattern of FCSEMS and PCSEMS was to reduce the incidence of migration with FCSEMS by leaving the proximal and distal flanges uncovered[38]. Stent migration is not only dependent on the stent design but also factors like the stent location, stent diameter, post-stenting chemotherapy or radiotherapy and use of clips or sutures[21,30]. Migration rates are higher when stents are placed through the gastroesophageal junction as the lower end of the stent projects freely and unsupported in the fundus of the stomach[34]. Baseline differences between the study groups for such confounding variables can introduce bias in the results of non-randomised studies. Another source of bias is the different types of SEMs used in the five studies of this review; with the greatest variation seen for FCSEMS. All four different types of FCSEMS used in the five studies have peculiar design elements to prevent stent migration. The European version of Z-stents are provided with one or two ring-shaped rows of barbs to prevent device migration[39]. The Niti-S stent flares to 26mm at both ends and has an internal covering of polyurethane to allow the outer uncovered Niti wire to embed in the esophageal wall[40]. Wallflex FCSEMS also has a dog-bone shaped design with an internal covering. The outer wire framework implants itself in the tumour wall providing frictional resistance to dislocation[29,36]. The fully covered SX-ELLA has a flip-flop type of anti-migration ring that is circumferentially attached to the proximal portion of the stent. The ring functions as a hook preventing stent migration[10,30]. Considering the anti-migration design elements incorporated in all FCSEMS, it is not surprising that our analysis found no statistical significant difference in the migration rates of the two devices. Our results seem robust as there was no change in the effect size or its direction after sub-group analysis of RCTs and non-RCTs.

Other than stent migration, stent obstruction due to tissue growth or food also results in recurrent dysphagia. Tissue obstruction can be either due to either tumour growth or hyperplastic non-malignant overgrowth[40]. With the development of covered SEMs, the incidence of stent obstruction due to tumour ingrowth has reduced but this advantage is probably outweighed by the high rate of tissue overgrowth at the edge of the stents[10]. Tissue growth may also manifest through the uncovered proximal and distal edges of PCSEMS and therefore these stents may be more prone to obstruction as compared to FCSEMS. Seven et al[21] in a retrospective study of 252 patients with benign and malignant esophageal lesions have reported a higher incidence of tissue ingrowth or outgrowth with PCSEMS as compared to FCSEMS (53.4 vs. 29.1 %, $p = 0.004$). The groups were however not matched with a greater number of malignant lesion treated with PCSEMS ($p < 0.001$). The results of our meta-analysis suggests that there is no difference between the two devices for rates of stent

obstruction with tissue growth. The results were similar for both RCTs and non-RCTs. It has been suggested that while using PCSEMS, selection of stent size should be based on the length of the covering rather than the complete length of the stent[27]. Overlaying the entire tumour length with the covered portion of PCSEMS may prevent malignant tissue ingrowth thereby reducing obstruction. Absence of any difference between FCSEMS and PCSEMS in our review may have been influenced by the stent size used in the individual studies.

Obstruction of the stent due to food has been attributed to lack of peristalsis and fixed diameter of the stent lumen. Blockage usually occurs due to a discrepancy in the size of the bolus and lumen of the stent or adherence of food to defects in the stent covering or in the uncovered portion of PCSEMS[26]. This may be one of the reasons for higher incidence of food obstruction seen with PCSEMS in our pooled analysis. However, the difference was not statistically significant. In addition to stent-related factors, patient compliance is important to prevent food obstruction. Clear and specific instruction to patients on having liquids between meals to flush the food and through chewing of food helps reduce the rate of food impaction[4]. For other complications, data only for chest pain and bleeding was pooled in our analysis. Retro-sternal pain after placement of SEMS has been attributed to the high axial force resulting in pressure on the malignant lesion[29]. Our analysis indicated that there is no difference between the two devices in terms of chest pain and bleeding. It is important to note that evidence is limited, as only three studies[27,29,30] were pooled for these variables.

Some limitations of our study need to be elaborated. Firstly, the overall quality of the included studies was not high. The risk of bias in individual studies may have compromised the level of evidence of our review. Secondly, only three RCTs[27–29] available for inclusion in the review. Non-randomised studies are prone to bias and may have influenced results. Thirdly, a variety of different stents with different design characteristics were used in the five trials. The influence of specific stent design on the overall outcome cannot be disregarded. Lastly, a meta-analysis on clinical outcomes and total overall complications was not possible due to the heterogeneity of the included studies.

Nevertheless, our study is the first meta-analysis comparing FCSEMS and PCSEMS for malignant esophageal lesions. The stability of results on sub-group analysis of RCTs and non-RCTs lends credibility to the inferences of our study.

Conclusions

To conclude, our results indicate that there is no difference in FCSEMS and PCSEMS in terms of successful stent placement, stent migration and stent obstruction when used for palliative treatment of inoperable esophageal malignancy. The quality of evidence is however weak and further high quality RCTs are required to enhance evidence on this subject.

In line with our results, it may be suggested that surgeons managing esophageal cancer may use any of the two stents without any difference in overall outcomes. However, in our opinion, individual patient characteristics and surgeon preference should continue to guide stent selection in patients with inoperable esophageal cancer.

Declarations

Abbreviations

SEMS, Self-expanding metal stents; FCSEMS, fully covered self-expanding metallic stents; PCSEMS, partially covered self-expanding metallic stents; RCT, Randomised controlled trial; CENTRAL, Cochrane Central Register of Controlled Trials; RoBANS, risk of bias assessment tool for non-randomized studies; CI, Confidence Interval; OR, Odds ratio

Ethical approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

This study is funded by Henan Science and Technology Department Project (No. 182102310573)

Competing interests

The authors declare that they have no competing interests

Authors' contributions

CW and YL conceived and designed the study. YL provided study materials. CW and HW were responsible for the collection and assembly of data, data analysis and interpretation. CW was involved in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

- [1]Kauppila JH, Mattsson F, Brusselaers N, Lagergren J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. *BMJ Open* 2018;8:e021495.
- [2]Allum WH, Griffin SM, Watson A, Colin-Jones D, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, British Society of Gastroenterology, et al. Guidelines for the management of oesophageal and gastric cancer. *Gut* 2002;50 Suppl 5:v1–23.
- [3]Halpern AL, McCarter MD. Palliative Management of Gastric and Esophageal Cancer. *Surg Clin North Am* 2019;99:555–69.
- [4]Kim KY, Tsauo J, Song HY, Kim PH, Park JH. Self-expandable metallic stent placement for the palliation of esophageal cancer. *J Korean Med Sci* 2017;32:1062–71.
- [5]Włodarczyk JR, Kuźdzał J. Stenting in Palliation of Unresectable Esophageal Cancer. *World J Surg* 2018;42:3988–96.
- [6]Bethge N, Sommer A, Gross U, von Kleist D, Vakili N. Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses. *Gastrointest Endosc* 1996;43:596–602.
- [7]Nelson DB, Axelrad AM, Fleischer DE, Kozarek RA, Silvis SE, Benjamin SB, et al. Silicone-covered Wallstent prototypes for palliation of malignant esophageal obstruction and digestive-respiratory fistulas. *Gastrointest Endosc* 1997;45:31–7.
- [8]van Boeckel PG, Siersema PD, Sturgess R, Dwyer L, Raijman I, Hirdes MM, et al. A new partially covered metal stent for palliation of malignant dysphagia: a prospective follow-up study. *Gastrointest Endosc* 2010;72:1269–73.
- [9]Uitdehaag MJ, van Hooft JE, Verschuur EML, Repici A, Steyerberg EW, Fockens P, et al. A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. *Gastrointest Endosc* 2009;70:1082–9.
- [10]Uitdehaag MJ, Siersema PD, Spaander MCW, Vleggaar FP, Verschuur EML, Steyerberg EW, et al. A new fully covered stent with antimigration properties for the palliation of malignant dysphagia: a prospective cohort study. *Gastrointest Endosc* 2010;71:600–5.
- [11]Siersema PD, Hop WC, van Blankenstein M, Dees J. A new design metal stent (Flamingo stent) for palliation of malignant dysphagia: a prospective study. The Rotterdam Esophageal Tumor Study Group. *Gastrointest Endosc* 2000;51:139–45.
- [12]Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009;6:e1000097.
- [13]Higgins J, Green S. *Cochrane Handbook for Systemic Reviews of Interventions*. Version 5. The Cochrane Collaboration; 2011.
- [14]Higgins J, Altman D, Sterne J. *Cochrane Statistical Methods Group and the Cochrane Bias Methods Group*. Chapter 8: assessing risk of bias in included studies. *Cochrane Handb. Syst. Rev. Interv. Version 5.*, The Cochrane Collaboration; 2011.
- [15]Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J Clin Epidemiol* 2013;66:408–14.
- [16]Uesato M, Akutsu Y, Murakami K, Muto Y, Kagaya A, Nakano A, et al. Comparison of Efficacy of Self-Expandable Metallic Stent Placement in the Unresectable Esophageal Cancer Patients. *Gastroenterol Res Pract* 2017;2017.
- [17]Battersby NJ, Bonney GK, Subar D, Talbot L, Decadt B, Lynch N. Outcomes following oesophageal stent insertion for palliation of malignant strictures: A large single centre series. *J Surg Oncol* 2012;105:60–5.
- [18]Eickhoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, et al. Konsekutiver vergleich von 3 verschiedenen typen selbstexpandierender metallstents zur palliation der malignen dysphagie: Ergebnisse aus dem prospektiven Ludwigshafener Ösophagus-Stentregister. *Z Gastroenterol* 2005;43:1113–21.
- [19]Gangloff A, Leclaire S, Di Fiore A, Huet E, Iwanicki-Caron I, Antonietti M, et al. Fully versus partially covered self-expandable metal stents in benign esophageal strictures. *Dis Esophagus* 2015;28:678–83.

- [20]Sabharwal T, Gulati MS, Fotiadis N, Dourado R, Botha A, Mason R, et al. Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: Proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. *J Gastroenterol Hepatol* 2008;23:723–8.
- [21]Seven G, Irani S, Ross AS, Ian Gan S, Gluck M, Low D, et al. Partially versus fully covered self-expanding metal stents for benign and malignant esophageal conditions: A single center experience. *Surg Endosc* 2013;27:2185–92.
- [22]Siersema PD, Hop WC, van Blankenstein M, van Tilburg AJ, Bac DJ, Homs MY, et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. *Gastrointest Endosc* 2001;54:145–53.
- [23]Van Heel NCM, Haringsma J, Boot H, Cats A, Vanhoutvin SALW, Kuipers EJ. Comparison of 2 expandable stents for malignant esophageal disease: A randomized controlled trial. *Gastrointest Endosc* 2012;76:52–8.
- [24]Wang MQ, Sze DY, Wang ZP, Wang ZQ, Gao YA, Dake MD. Delayed complications after esophageal stent placement for treatment of malignant esophageal obstructions and esophagorespiratory fistulas. *J Vasc Interv Radiol* 2001;12:465–74.
- [25]Wang C, Lu J, Wang Y, Li GZ, Li JLT, Chen L. NON-VASCULAR INTERVENTIONS A New Fully Covered Irradiation Stent Versus a Partially Covered Irradiation Stent for Unresectable Malignant Dysphagia: A Single-Center Experience. *Cardiovasc Intervent Radiol* 2019;42:1142–52.
- [26]Homs MY V, Steyerberg EW, Kuipers EJ, van der Gaast A, Haringsma J, van Blankenstein M, et al. Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma. *Endoscopy* 2004;36:880–6.
- [27]Verschuur EML, Repici A, Kuipers EJ, Steyerberg EW, Siersema PD. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: A randomized trial. *Am J Gastroenterol* 2008;103:304–12.
- [28]Persson J, Smedh U, Johnsson Å, Ohlin B, Sundbom M, Nilsson M, et al. Fully covered stents are similar to semi-covered stents with regard to migration in palliative treatment of malignant strictures of the esophagus and gastric cardia: results of a randomized controlled trial. *Surg Endosc* 2017;31:4025–33.
- [29]Didden P, Reijm AN, Erler NS, Wolters LMM, Tang TJ, Ter Borg PCJ, et al. Fully vs. partially covered selfexpandable metal stent for palliation of malignant esophageal strictures: A randomized trial (the COPAC study). *Endoscopy* 2018;50:961–71.
- [30]Alonso Lárraga JO, Flores Carmona DY, Hernández Guerrero A, Ramírez Solís ME, de la Mora Levy JG, Sánchez del Monte JC. Fully covered stents versus partially covered stents for palliative treatment of esophageal cancer: Is there a difference? *Rev Gastroenterol Mex* 2018;83:228–33.
- [31]Dakkak M, Bennett JR. A new dysphagia score with objective validation. *J Clin Gastroenterol* 1992;14:99–100.
- [32]Ogilvie AL, Dronfield MW, Ferguson R, Atkinson M. Palliative intubation of oesophagogastric neoplasms at fiberoptic endoscopy. *Gut* 1982;23:1060–7.
- [33]Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. *Eur J Cancer* 2007;43:2066–73.
- [34]Siersema PD, Marcon N, Vakili N. Metal stents for tumors of the distal esophagus and gastric cardia. *Endoscopy* 2003;35:79–85.
- [35]Knyrim K, Wagner H-J, Bethge N, Keymling M, Vakili N. A Controlled Trial of an Expansile Metal Stent for Palliation of Esophageal Obstruction Due to Inoperable Cancer. *N Engl J Med* 1993;329:1302–7.
- [36]Repici A, Jovani M, Hassan C, Solito B, Di Mitri R, Buffoli F, et al. Management of inoperable malignant oesophageal strictures with fully covered wallflex® stent: A multicentre prospective study. *Dig Liver Dis* 2014;46:1093–8.
- [37]Saranovic D, Djuric-Stefanovic A, Ivanovic A, Masulovic D, Pesko P. Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types. *Dis Esophagus* 2005;18:230–8.
- [38]Law R, Baron TH. Choosing the Appropriate Esophageal Stent for Your Patient. *Am J Gastroenterol* 2016;111:1669–71.
- [39]Eil C, May A. Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: A critical review. *Endoscopy* 1997;29:392–8.
- [40]Verschuur EML, Homs MY V, Steyerberg EW, Haringsma J, Wahab PJ, Kuipers EJ, et al. A new esophageal stent design (Niti-S stent) for the prevention of migration: A prospective study in 42 patients. *Gastrointest Endosc* 2006;63:134–40.

Tables

Table 1: Search queries and results for PubMed database.

Search	Query	Items found
1	Search ((esophagus) AND malignancy) AND stent	753
2	Search (esophageal dysphagia) AND metallic stent	251
3	Search (esophageal dysphagia) AND palliative treatment	1293
4	Search (esophageal dysphagia) AND stent	1158
5	Search (esophageal cancer) AND metallic stent	398
6	Search (esophageal cancer) AND palliative treatment	3010
7	Search (esophageal cancer) AND stent	1821

Table 2: Details of excluded studies

Study	Reason for exclusion
Uesato et al[16]	Less than five patients in FCSEMS group
Battersby et al[17]	Separate data not available for different stents used
Eickhoff et al[18]	German language article
Gangloff et al[19]	Used stents for benign growths
Sabharwal et al[20]	Used stent with anti-reflux mechanism
Seven et al[21]	Used stents for benign growths
Siersema et al[22]	Overlapping data with Homs et al[26]
Van Heel et al[23]	Compared two PCSEMS
Wang et al[24]	Compared uncovered vs covered stents
Wang et al[27]	Compared irradiated stents

FCSEMS, Fully-Covered Self Expanding Metal Stents; PCSEMS, Partially-Covered Self Expanding Metal Stents

Table 2: Characteristics of included studies

or/year	Study type	Type of FCSEMS	Type of PCSEMS	Number of patients		Pre/post - Chemoradiotherapy		Dysphagia grade		Tu
				FCSEMS	PCSEMS	PCSEMS	PCSEMS	FCSEMS	PCSEMS	
aga et al[16]/2018	Retrospective	SX-ELLA® (ELLA-CS, Hradec Králové, Czech Republic)	Ultraflex® NG, (Boston Scientific, Natick, Massachusetts, USA)	21	29	Pre: 12 Post: 13	Pre: 12 Post: 13	Grade 3: 10 Grade 4: 11	Grade 3: 13 Grade 4: 16	P: Proximal M: Mid D&C: Distal esophagus and cardia
en et al[17]/2018	RCT	WallFlex fully covered stent (Boston Scientific, Natick, Massachusetts, USA)	WallFlex partially covered stent (Boston Scientific, Natick, Massachusetts, USA)	48	49	Pre: 41 Post: 5	Pre: 41 Post: 5	2.8±0.7	2.8±0.8	P: Proximal M: Mid D&C: Distal esophagus and cardia
son et al[18]/2017	RCT	WallFlex fully covered stent (Boston Scientific, Natick, Massachusetts, USA)	Ultraflex® NG, (Boston Scientific, Natick, Massachusetts, USA)	48	47	NR	NR	2±NR	3±NR	NR
chuur et al[19]/2008	RCT	Niti-S stent (Taewoong Medical, Seoul, Korea)	Ultraflex® NG, (Boston Scientific, Natick, Massachusetts, USA)	42	42	Pre:11 Post: 15	Pre:11 Post: 15	3±NR	3±NR	M: Mid D&C: Distal esophagus and cardia
s et al[20]/2004	Prospective	Z-stent (Wilson-Cook Europe, Bjaeverskov, Denmark)	Ultraflex® NG, (Boston Scientific, Natick, Massachusetts, USA) And Flamingo Wallstent (Microvasive/Boston Scientific)	70	Ultraflex:75 Flamingo:71	Ultraflex: Pre: 17 Post: 6 Flamingo: Pre: 23 Post: 4	Ultraflex: Pre: 17 Post: 6 Flamingo: Pre: 23 Post: 4	3.2±0.5	Ultraflex: 3±0.7 Flamingo: 3.2±0.5	M: Mid D&C: Distal esophagus and cardia

FCSEMS; Fully covered- Self expanding metallic stents; PCSEMS, Partially covered- Self expanding metallic stents; RCT, Randomized controlled study; P, proximal esophagus; M, mid-esophagus; D&C, Distal esophagus and cardia; NR, Not reported

Table 4: Outcomes of included studies

Outcome	Lárraga et al[30]		Didden et al[29]		Persson et al[28]		Verschuur et al[27]		Homs et al[26]		
	FCSEMS	PCSEMS	FCSEMS	PCSEMS	FCSEMS	PCSEMS	FCSEMS	PCSEMS	FCSEMS	PCSEMS	PCSEMS
	N=21	N=29	N=48	N=49	N=48	N=47	N=42	N=42	N=70	(Ultraflex) N=75	(Flamingo) N=71
Stents	21	29	48	47	45	43	40	42	NR	NR	NR
Stent placement	4	5	4	3	9	14	5	7	4	17	5
Stent migration	0	5	5	7	0	2	10	13	11	7	12
Stent fracture	2	2	0	1	0	5	1	0	1	10	5
Pain	1	2	9	9	NR	NR	2	1	NR	NR	NR
Angiography	0	1	4	5	NR	NR	2	5	NR	NR	NR

FCSEMS; Fully covered- Self expanding metallic stents; PCSEMS, Partially covered- Self expanding metallic stents; NR, Not reported

Table 5: Risk of Bias summary for RCTs

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other Biases
Didden et al[29]	Low risk	Low risk	High risk	High risk	Low risk	Low risk	Unclear risk
Persson et al[28]	Low risk	Unclear risk	Low risk	High risk	High risk	Unclear risk	Unclear risk
Verschuur et al[27]	Low risk	Unclear risk	High risk	High risk	High risk	Unclear risk	Low risk

Table 6: Risk of bias summary for Non-RCTs

Study	Selection of participants	Confounding variables	Intervention measurements	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting
Lárraga et al[30]	Low risk	High risk	Unclear risk	High risk	Low risk	Low risk
Homs et al[26]	Low risk	Low risk	High risk	High risk	Low risk	Low risk

Figures




Figure 1

Flow chart of the study




Figure 2

Forrest plot for technical success




Figure 3

Forrest plot for stent migration




Figure 4

Forrest plot for stent obstruction by tissue growth




Figure 5

Forrest plot for stent obstruction by food




Figure 6

Forrest plot for bleeding




Figure 7

Forrest plot for chest pain

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMA2009checklist.doc](#)